Basel, Switzerland, 2007/02/27
Swiss-based computational biology provider Genedata AG announces its participation in BaSysBio, an integrated systems biology project involving 15 research organizations from nine European countries.
BaSysBio (Bacillus Systems Biology) will study the global regulation of gene transcription in the model bacterium Bacillus subtilis. This bacterium has significant economic potential as a producer of enzymes and metabolites, and is used in a wide range of industries, from pharmaceutical and chemical manufacturers to the agro and food sectors. Two disease-causing bacteria, Bacillus anthracis, responsible for Anthrax, and Staphylococcus aureus, responsible for secondary infections, are objects of research as well.
BaSysBio will provide new insight into the fundamental principles that control cellular processes. Subsequently, the initiative will contribute to the identification of new biomarkers, and innovative therapeutic targets for anti-bacterial drugs.
Genedata Phylosopher® has been chosen as the central management and infrastructure solution for sharing and interpreting the experimental data generated within BaSysBio. The project will adapt an array of high-throughput genomics technologies, including transcriptomics, proteomics, metabolomics, fluxomics and cell reporter assays. As quantitative molecular profiling information is key for the development of predictive mathematical models, the Genedata Phylosopher tools will be used for integrating the BaSysBio data and interpreting it in its pathway context. “Thanks to Genedata we are able to pool the various partners’ genomics and systems biology expertise across the entire network,” BaSysBio project coordinator Dr. Philippe Noirot said.
For Genedata, anticipating the evolving needs of systems biology research is an important commitment and responsibility . The company currently supports several systems biology research consortia in Europe. Dr. Othmar Pfannes, CEO of Genedata AG, stated: “The project brings together the best teams in Europe, specialized in different fields from molecular biology to computational biology. We are proud to collaborate with this world class research consortium.”
Contact:
Genedata AG
Dr. Tobe Freeman
Manager Public Relations
Phone +41 61 697 85 10
Fax +41 61 697 7244
tobe.freeman@genedata.com
www.genedata.com
BaSysBio
Dr. Philippe Noirot
Project Coordinator
Phone +33 1 34 65 2514
Philippe.Noirot@jouy.inra.fr
BaSysBio (Bacillus Systems Biology) is an European integrated project for the development of systems biology techniques. These techniques will contribute to a better understanding of the global structure of the regulatory networks that control bacterial metabolism, and subsequently create new opportunities in the health and environmental field. BaSysBio was launched on December 1, 2006, with a total contribution of 12 Mio € from the European Union for the 15 research organizations from nine European countries.
Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The company offers expertise in research informatics combined with open and scalable computational solutions, including Genedata Phylosopher® for integrating, structuring, analyzing research data, Genedata Screener® for high throughput screening analysis, and Genedata Expressionist® for drug safety studies and for toxico-genomics. Founded in 1997 as a privately held spin-off from Novartis, Genedata is headquartered in Basel, Switzerland, and has branches in Munich (Germany), Boston and San Francisco (USA) and Tokio (Japan).
For more information about Genedata, please visit: www.genedata.com.
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Related Files:
Download PDF version